Revolutionary UTI Vaccine Ignored by NHS

Women suffering from persistent bladder infections are incurring significant costs for a novel vaccine, Uromune, because the NHS currently offers limited funding. This pineapple-flavoured mouth spray has demonstrated efficacy in trials for preventing recurrent urinary tract infections (UTIs) for nearly a decade.

While available privately in the UK for around £400, and used internationally, its restricted NHS provision is questioned by experts. They are calling for the NHS to offer Uromune to patients experiencing at least three UTIs annually, a move that could grant access to 1.7 million women.

The vaccine works by stimulating the immune system against common UTI-causing bacteria. Despite its promise and ongoing regulatory review, experts argue that patients should not endure prolonged suffering while awaiting potential future NHS approval, highlighting international examples of broader access.